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Summary
Background: Cisplatin is one of the most active cytotoxic
agents available for the treatment of patients with head and
neck cancer. In a previous phase II study with weekly admin-
istration of cisplatin, a response rate of 51% was achieved.
However, only in a minority of the patients the planned high
dose intensity of 80 mg/m2/week could be reached because of
toxicity, mainly thrombocytopenia and ototoxicity. Amifostine
is a cytoprotective drug that can diminish the toxicity of
alkylating agents and platinum compounds. Therefore the
effect of amifostine on toxicity and activity of weekly cisplatin
was investigated in a randomized study.
Patients and methods: Patients with locally advanced, re-
current or metastatic head and neck cancer were eligible.
Patients were randomized to weekly cisplatin 70 mg/m2 for six
cycles preceded by amifostine 740 mg/m2, or cisplatin only.
Cisplatin was administered in hypertonic saline (3% NaCl) as
a one-hour infusion; amifostine was administered as a 15-
minute infusion directly before the administration of cisplatin.
Results: Seventy-four patients were entered in the study. The
median number of cisplatin administrations was 6 (range 2-6),
equal in both arms. In both treatment arms the median dose
intensity of cisplatin achieved was the planned 70 mg/m2/week.
In the cisplatin only arm 6 out of 206 cycles were complicated
by thrombocytopenia grade 3 or 4 versus 1 of 184 cycles in the
amifostine arm (P = 0.035). Hypomagnesaemia grade 2 + 3
was significantly less observed in the amifostine arm (P = 0.04).
Neurotoxicity analyzed by serial vibration perception thresh-
olds (VPT) showed a diminished incidence of subclinical
neurotoxicity in the amifostine arm (P = 0.03). No protective
effect on renal and ototoxicity could be shown. Hypotension
was the main side effect of amifostine but only of relevance in
one patient. The antitumor activity of cisplatin was preserved
as 63% of the evaluable patients in the amifostine arm re-
sponded compared to 50% of the evaluable patients in the
cisplatin alone arm.
Conclusion: Our study indicated that in combination with
weekly administered cisplatin amifostine reduced the risk of
thrombocytopenia, hypomagnesemia as well as subclinical
neurotoxicity, but did not result in a higher dose intensity of
cisplatin. Addition of amifostine did not compromise the anti-
tumor effect of cisplatin.
Key words: amifostine, cisplatin, cytoprotection, head and
neck cancer
Introduction
Approximately 50%-60% of the patients with head and
neck cancer present at diagnosis with a locally advanced
tumor stage III or IV. Treatment usually consists of
surgery followed by radiotherapy or of high dose radio-
therapy. However, these treatments yield a cure rate of
only 30%-40%. Most patients will recur locoregionally,
while 10%-15% will die from distant metastases [1].
Locally advanced head and neck cancer is highly respon-
sive to chemotherapy. The combinations of cisplatin
with both bleomycin and methotrexate or with a 96-hour
continuous infusion of fluorouracil are considered to be
the most active regimens with response rates of 60%-
90%, of which 30%-35% complete [2, 3]. The contribu-
tion of induction chemotherapy on survival in locally
advanced head and neck cancer is however, not clear [4].
In locally recurrent or metastatic disease the results of
chemotherapy are very disappointing with response
rates of only 20%-30%, of short duration and without
demonstrable effect on survival [4].
For cisplatin a dose-response relation is suggested in
several tumor types [5]. Therefore clinical studies with
high-dose and high-dose intensity regimens are attrac-
tive. As nausea and vomiting can be treated more effi-
ciently and as with vigorous hydration and the admin-
istration of cisplatin in hypertonic saline the risk of
nephrotoxicity can be reduced [6, 7], neuro- and ototox-
icity are now the most cumbersome cisplatin toxicities.
In a phase II study of weekly cisplatin at a planned dose
of 80 mg/m2/week for six cycles in locally far advanced
head and neck cancer a response was obtained in 51% of
the patients, suggesting that cisplatin administered at a
higher dose intensity is more active than at standard
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doses. With this weekly schedule hematologic toxicity,
especially thrombocytopenia, was the main reason for
treatment delays or the reason to take patients off study.
Other major toxicities were hypomagnesemia grade 2 +
3 in 20%, ototoxicity grade 2 + 3 in 18% and nephrotox-
icity grade 2 + 3 in 5% of the patients [8]. Because of
these side effects, only 9 out of 59 patients completed the
treatment without interruption and reached the planned
dose intensity of 80 mg/m2/week.
Amifostine (WR-2721; Ethyol®) is an organic thio-
phosphate. In preclinical and clinical studies amifostine
showed selective protection of normal tissues against
radiation-induced toxicities and toxicities induced by
alkylating agents and platinum compounds without in-
fluencing the anti-tumor effects of these treatments [9-
14]. Amifostine is a prodrug that has to be converted
into the active metabolite, the free thiol WR-1065.
Selective protection of normal tissues is explained by
the more rapid uptake of WR-1065 in normal cells as
compared to tumor cells, which is due to the difference
in membrane- and capillary bound alkaline phosphatase
and differences in pH between normal and tumor cells
[15]. As amifostine has a very short plasma half-life
(< 10 minutes), the drug has to be administered directly
before the administration of chemotherapy [15, 16]. Spe-
cific side effects reported of amifostine are hypotension,
nausea, vomiting, sneezing, flushing, mild somnolence,
hypocalcaemia (mostly asymptomatic) and very rarely
allergic reactions [17, 18].
The EORTC Head and Neck Cancer Cooperative
Group decided to explore the weekly cisplatin regimen
in a randomized study comparing weekly cisplatin to
weekly cisplatin with amifostine.
Patients and methods
Patients in this study were required to have a histologic proof of
squamous cell carcinoma of the mucous membranes of the head and
neck, locally advanced disease stage III or IV. locally recurrent disease
after previous radiotherapy and/or surgery or with distant metastases
and with measurable lesions on CT-scan or MRI. Prior chemotherapy
was not allowed with the exception of neoadjuvant chemotherapy > 12
months before entering this study. Further entry criteria included age
between 18 and 70 years. WHO performance status ^ 2 , WBC count
>4.0 x 1O9/1, platelet count > 100 x 1O9/1. serum creatinine <120
umol/l or creatinine clearance > 6 0 ml/min. liver function tests and
bilirubin <2 .0x the upper limit of the normal range, no suspicion of
active infection. Excluded from the study were patients with undiffer-
entiated carcinoma of the nasopharynx, patients with hypertension
requiring more intensive medication than diuretics only, patients with
concomitant neurological, psychological or medical disorders making
them unsuitable for treatment or follow-up per protocol and patients
with CNS involvement. All patients gave written informed consent.
Before the start of treatment patients had a full clinical work up
with medical history, physical examination, measurement of indicator
lesions, full hematological counts and serum chemistries, creatinine
clearance. ECG. chest X-ray, baseline audiometry and neurologic
examination, including estimation of the vibration perception threshold
(VPT). The VPTwas measured at the dorsum of the second metacarpal
bone of both hands. All centers made use of a Vibrameter type IV
(Somatic AB. Stockholm, Sweden).
During treatment the patients had weekly a medical history and
physical examination taken, weekly determination of full blood counts,
serum chemistries and creatinine clearance. Neurologic examination
and audiometry were repeated after the 3rd and 6th cisplatin admin-
istration and. if possible, three and six months later.
Patients were registered and randomized at the EORTC New Drug
Development Office in Amsterdam. Patients were stratified by institu-
tion and by disease extent (locally advanced versus locally recurrent or
metastatic disease).
Response to treatment was assessed two weeks after the last
cisplatin dose. The WHO criteria for evaluation of response were used;
toxicity. with exception of amifostine-induced hypotension, was graded
according to the NCI-CTC criteria.
For grading of amifostine related hypotension a modified grading
system was used:
Grade 0 No hypotension.
Grade 1 Hypotension not requiring amifostine interruption.
Grade 2 Hypotension requiring interruption once.
Grade 3 Hypotension requiring interruption more than once.
Grade 4 Prolonged hypotension requiring dose reduction.
Grade 5 Hypotension accompanied by complications or requir-
ing other therapy than rapid saline infusion.
Study design
Before starting the randomized study a feasibility study was performed
in 14 patients to estimate the optimal amifostine dose and antiemetic
schedule [19]. The feasibility study was considered necessary because
experience with weekly administration of amifostine with cisplatin was
lacking. An amifostine dose of 740 mg/m2 was in that study better
tolerated than the usual 910 mg/m2. The subject of the randomized
study was to compare toxicity and efficacy of both schedules. Based on
the results of other studies, which showed considerable reduction of
nephro- and neurotoxicity [11, 12], it was postulated that 30 fully
evaluable patients per treatment arm would be sufficient to detect a
significant reduction in nephro- and neurotoxicity [20]. After the
randomized study a cisplatin-dose escalation study was planned in
case a significant protective effect of amifostine was shown.
Treatment schedule
Patients were hospitalized weekly for 24 hours
Antiemetic regimen
The antiemetic regimen consisted of tiethylperazine 6.5 mg p.o. four
hours and 30 minutes before chemotherapy combined with ondanse-
tron 8 mg 30 minutes before and 8 mg eight hours after chemotherapy
plus dexamethasone 20 mg 30 minutes before and eight hours after
chemotherapy.
Cisplatin
Standard prehydration consisted of 1 liter of normal saline or dextrose/
saline with suppletion of 20 mmol KG and 2 g MgSO4 and was given
over two hours. Cisplatin powder was dissolved in 250 ml of hyper-
tonic saline (NaCI 3%) and administered at a dose of 70 mg/m2 over
one hour followed by posthydration with 4 liters of normal saline or
dextrose/saline (with 80 mmol KC1 and 8 g of MgSO4) over 24 hours.
In case of urine output < 100 ml/hour 100 ml of mannitol 20% and/or
10 mg furosemide was administered depending on the local practice of
the institute.
Amtfosline
Amifostine was supplied by USB Pharma Ltd. Watford. UK. Amifostine
was dissolved in normal saline to a concentration of 50 mg/ml and was
administered at a dose of 740 mg/m2 as a rapid infusion over 15
minutes directly before the cisplatin was given. During the amifostine
administration patients were kept in the supine position and blood
pressure was measured at least e\ery five minutes.
Before starting amifostine a threshold blood pressure was deter-
mined under which value amifostine had to be interrupted. The
threshold mean s>stolic blood pressure was calculated by taking the
average of three blood pressures taken within two hours before the
amifostine administration.
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The guideline for interruption of amifostine was:
Mean baseline blood pressure in mm Hg
<100 100-119 120-139 140-180 >180
Decrease in systolic
BP(mmHg) 20 25 30 40 50
In case of a drop in blood pressure below the calculated threshold the
amifostine infusion was interrupted and infusion of normal saline
started. In case of return of blood pressure above the threshold within
five minutes the amifostine infusion was restarted. In case the hypo-
tension lasted > 5 minutes amifostine was further withheld for that
cycle and for the next cycle the amifostine dose was reduced by 25%.
Dose reductions of cisplatin were not allowed in this study. If at
planned retreatment WBC were <2.5 x 109/l and/or platelets were
<75 x 109/l the treatment was postponed until recovery above these
values In case of a treatment delay > 2 weeks patients were taken off
study. The development of nephro- or neurotoxicity grade 2 and the
development of clinical hearing loss were also reasons to take a patient
off study.
Statistics
Percentages were compared using the chi-square test (without correction
for continuity). Variables with an approximately continuous distribu-
tion were compared between treatment groups with the signed-rank
Mann-Whitney U-test. For comparisons over time within treatment
groups the signed rank test of Wilcoxon was used (Stata 3.1; Stata
Corporation, TX).
Results
Seventy-four patients were randomized in the study. The
patient characteristics are shown in Table 1. Both groups
were well balanced according to gender, age and disease
extent. Three patients pretreated with neoadjuvant
chemotherapy > 1 year before, were randomized to the
cisplatin-amifostine arm. One patient randomized to the
cisplatin-amifostine arm never started treatment and is
excluded from the analysis.
In the amifostine arm in total 184 cycles of cisplatin
were administered compared to 206 cycles in the cisplatin
only arm (P = 0.06). In both treatment arms the median
number of cisplatin administrations was 6 (range 2-6).
The median cisplatin dose intensity achieved was equal
in both treatment arms: 70 mg/m2/week. The results are
given in Table 2.
In the cisplatin-amifostine arm 20 patients com-
pleted six cycles (56%) versus 28 patients in the cisplatin
only arm (76%) (P = 0.07). The main reason for this
difference between both arms is the early death of three
patients in the amifostine arm (two patients with known
cardiovascular disease died at home, one patient died of
asphyxia). Other reasons not to complete the six cycles
in the combination arm were: progressive disease in
three patients, delay due to leucopenia > 2 weeks in
four patients, ototoxicity in three patients, pneumonia
in one patient, a protocol violation in one patient and in
one patient the reason was 'physicians preference' be-
Table I. Patient characteristics randomized study.
Number of patients entered
Number of patients treated
Sex
Male
Female
Age (in years)
Median
Range
Performance status
Median
Range
Disease status
Locally advanced
Locally recurrent
Metastatic
Prior radiotherapy
Prior neoadjuvant chemotherapy
Localization primary tumor
Oral cavity
Oropharynx
Hypopharynx
Larynx
Nasopharynx
Maxillary sinus
Differentiation grade
Well differentiated
Moderately differentiated
Poorly differentiated
Cisplatin +
amifostine
37
36
27
10
54
35-69
1
0-2
29
5
3
9
3
4
17
10
3
2
1
19
14
4
Table 2. Treatment results randomized study.
Number of patients treated
Total number of cycles
Number of cycles per patient
Median
Range
Patients completing six cycles
Without delay
Number of patients with delays
For myelosuppression
Total number of weeks delayed for
myelosuppression
Median cisplatin dose intensity
achieved (mg/m2/week)
Reasons for < 6 cycles
Progressive disease
Early death
Hematologic toxicity
Ototoxicity
Infection
Protocol violation
Physician preference
Cisplatin +
amifostine
36
184
6
2-6
20
15
5
2
15
70
3
3
4
3
1
1
1
Cisplatin
37
206
6
2-6
28
20
9
8
25
70
2
0
3
3
1
0
Cisplatin
only
37
37
28
9
54
36-67
1
0-1
29
7
1
7
0
7
15
11
3
1
0
15
15
7
P-value
0.06
0.07
0.29
0.08
0.17
cause of planning of additional radiotherapy. The rea-
sons not to complete six cycles in the cisplatin only arm
were progressive disease in one patient, delay > 2 weeks
due to hematologic toxicity in four patients (neutropenia
in two and combination of neutro-and thrombocyto-
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Table 3 Toxicity analysis. CTC-grading. worst toxicity per patient. Table 4. Renal toxicity.
Cisplatin +
amifostine (grade)
I 2 3 <
Cisplatin only
(grade)
1 3
Anemia 11 19 2 0 14 15 3 0
Leucopenia 8 11 2 2 4 10 5 0
Neutropenia 5 9 8 2 5 6 10 1
Thrombocytopenia 19 7 0 I 11 4 2 3
Nephrotoxicity 6 2 0 0 4 0 0 0
Ototoxicity 6 6 3 0 3 1 0 4 0
Neurotoxicity 4 0 0 0 5 0 0 0
Nausea 12 13 3 0 18 6 2 0
Vomiting 9 1 3 3 2 6 9 3 0
Diarrhea 2 0 1 0 5 2 0 1
Stomatitis 2 1 0 0 2 0 0 0
Hypocalcemia 6 2 2 0 7 2 1 0
Hypokalemia 7 0 0 1 7 5 0 0
Hypomagnesemia 8 6 0 0 7 7 7 0
Hyponatremia 13 4 0 0 17 4 3 0
Hypophosphatemia 5 1 1 0 7 0 0 0
Alopecia 1 0 0 0 2 0 0 0
Weight loss 6 3 0 0 8 3 0 0
Hypotension" 4 6 2 3
a
 Amifostine induced hypotension, for grading see 'Patients and
methods'.
penia in two), ototoxicity in three patients and a pneu-
monia in one patient.
Toxicity analysis
Hematologic toxicity
The hematologic toxicity is presented in Table 3. There
was no difference in the occurrence of leucopenia
(P - 0.76) and neutropenia {P - 0.98) between the two
arms when analyzed per patient, nor when analyzed per
cycle (P = 0.130 and P = 0.953, respectively). In the
cisplatin only arm thrombocytopenia grade 3 + 4 was
observed in five versus one patients in the combination
arm (P = 0.10) and in 6 of 206 cycles in the cisplatin only
versus 1 of 184 cycles in the combination arm (P - 0.035).
In the combination arm four patients were taken off
study because of treatment delay > 2 weeks due to slow
bone marrow recovery (three patients with leucopenia
and one patient with both leuco-and thrombocytopenia)
and three patients in the cisplatin alone arm (two pa-
tients because of thrombocytopenia and one patient
because of neutropenia). The total number of weeks
delayed because of haematologic toxicity was not
different between both arms: 15 weeks delay in the
combination arm and 25 weeks in the cisplatin only
arm (P = 0.17).
Neph ro toxic it i •
Nephrotoxicity grade 2, based on serum creatinine levels,
was reported in two patients in the amifostine arm; one
of the patients was taken off study after the fourth
cisplatin administration during neutropenic fever and in
the second patient grade 2 nephrotoxicity was reported
Cycle Number of patients Median creatinine clearance" ml/min
Cisplalin + Cisplalin
amifostine only
Cisplatin +
amifostine
Cisplatin
only
P-value
36
36
34
31
27
20
Post 6 20
37
37
35
34
31
28
28
82
82
87
86
87
84
89
97
91
90
85
85
82
81
0.09
0 38
0.44
0.82
0.46
0 83
0.32
a
 Calculated creatinine clearance by Cockroft-Gault formula.
after completion of treatment. In both patients the
serum creatinine returned to baseline level during fol-
low-up. Nephrotoxicity grade 1 was reported in five
patients in the cisplatin only and in six patients in the
combination arm. When creatinine clearances (calcu-
lated with the Cockroft-Gault formula) were compared
cycle by cycle no differences between both treatment
arms could be shown (Table 4). Although the median
creatinine clearance decreased in the cisplatin only arm
from 97 ml/min to 81 ml/min after six cisplatin cycles
while the median clearance remained at least stable
in the cisplatin-amifostine arm this difference was not
statistically significant (P = 0.12; Mann-Whitney U-test).
Hypomagnesemia/hyponatremia
Hypomagnesemia grade 2 + 3 was observed in six
patients in the combination arm versus in 14 patients in
the cisplatin only arm (P - 0.04); there were 8 cycles in
the combination arm complicated by hypomagnesaemia
> grade 1 versus 27 cycles in the cisplatin only arm
(P — 0.004). Clinical side effects related to hypomagne-
semia were not reported. In the cisplatin only arm four
patients had hyponatremia grade 3 + 4 versus none in
the amifostine-arm (P = 0.04), but when hyponatraemia
is analysed cycle by cycle this difference is not significant
(P = 0.163).
There were no significant differences between both
treatment arms in the occurrence in hypokalaemia,
hypocalcaemia or hypophosphatemia.
Neurotoxicity
Clinical neurotoxicity grade 1 was reported in four
patients in the combination arm and five patients in the
cisplatin only arm. As neurotoxicity can develop after
cessation of treatment the clinical neurotoxicity grading
was based on worst symptoms up to three months after
treatment. For the same reason the VPT analysis was
done in patients in whom three-month VPT values were
available. The mean cumulative cisplatin dose in the
analyzed patients was 394 mg/m2 in the combination
arm versus 401 mg/m2 in the cisplatin only arm. Details
are shown in Table 5. VPT was measured at the dorsum
of the second metacarpal bone of both hands and was
recorded in micrometers of skin displacement. Per VPT-
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examination three measurements were done and the
mean of these three values was taken as value for the
VPT as described previously [25]. In the table the
median of these VPT-means are reported. The VPTs of
the left hand show less increase in the amifostine arm
compared to the cisplatin alone arm (P = 0.03). Due to
an imbalance at baseline for the cisplatin-amifostine
arm for VPT values of the right hand (due to the limited
number of data) the increase of the VPTs for the right
hand is not significant different (P = 0.07). This imbal-
ance is probably caused by the low number of patients
analyzed at three months as the median VPT for the
right hand at baseline, when all patients in the amifos-
tine arm are considered, was 0.73, identical to the VPT-
values of the left hand.
Ototoxicity
Although tinnitus was reported less frequent in the
amifostine arm there was no difference in the occur-
rence of clinical ototoxicity grade 2 + 3 between both
treatment arms (P = 0.24). Ototoxicity grade 3, clinical
hearing loss, was reported in three patients in the com-
bination arm and four patients in the cisplatin alone
arm. Analysis of the serial audiometries in both arms of
the study showed that hearing loss was only seen at the
high-frequency levels (4000 and 8000 Hz). At 4000 Hz
the median hearing loss was 15 decibels (db) in both
ears, equal in both treatment arms. At 8000 Hz the
median hearing loss was 30 db in both ears in the
amifostine arm and 25 db in the right and 35 db in the
left ear in the cisplatin only arm.
As many patients had already impaired hearing func-
tion at baseline, patients with 'normal' ears at baseline
(<30 db hearing loss at 4000 and 8000 Herz) were
analyzed separately. Also in this small subgroup (only
six patients in the amifostine arm and nine in the cis-
platin only arm) no difference in the audiologic param-
eters could be shown.
Gastrointestinal toxicity
Nausea and vomiting were reported slightly more fre-
quent in the combination arm, not unexpected, as ami-
fostine itself could cause these side effects. Vomiting
grade 4 was reported in two patients in the amifostine
arm. Other gastrointestinal side effects were equal in
both treatment arms.
Amifostine toxicities
Hypotension (for grading system see section 'Patients
and methods') during the infusion of amifostine was
reported in 17 patients (47%) and in 45 out of 184 cycles
(24%). Hypotension grade 3 was reported in two pa-
tients (three cycles) and grade 4 hypotension in three
patients (four cycles), and occurred only during the first
or second amifostine administration. In two patients
hypotension did not recur after a 25% dose reduction
according to the protocol. In one patient, grade 4 hypo-
tension recurred despite dose reduction and amifostine
was further withheld in this patient.
Table 5. Neuroloxicity. VPTanalysis (median values).
Left hand baseline (all patients)
Right hand baseline (all patients)
Left hand baseline"
Left hand three monlhsa
Right hand baseline1*
Right hand three months'1
Cisplatin +
amifostine
0 77
0.73
0.70
0.85
0.58
0.86
Cisplatin
0.77
0.74
0.65
1.13b
0 75
1.15C
d
 Patients with VPT values at baseline and after three months follow-up'
Fourteen patients in the cisplatin + amifostine arm: twenty patients in
the cisplatin only arm.
b
 P = 0.03 and ' P = 0.07 for difference in increase of VPT after
treatment.
One patient died shortly after the second amifostine
administration. This patient, with an obstructive local
recurrence of oropharyngeal cancer, suffered from a
hypotension (RR 70/50) nine minutes after the start of
amifostine and the administration was interrupted.
Shortly thereafter the patient became dyspnoeic because
of airway obstruction by tough sputum, became uncon-
sciousness and died shortly thereafter. The postmortem
revealed asphyxia due to mechanical obstruction and
pulmonary edema.
Other, minor, side effects of amifostine reported were
dizziness (seven patients), flushing (six patients), feelings
of anxiety (two patients), palpitations (three patients) and
collapse (one patient) due to episodes of hypotension. A
typical amifostine side effect is sneezing. This side effect
was reported by six patients. Dizziness was also reported
by five patients in the cisplatin only arm.
Response analysis
Although the main goal of the randomized study was
comparison of toxicity all X-rays, CT-scans and MRI's
of all responding patients as well as an at random
selection of non-responding patients were independently
reviewed by a radiologist experienced in head and neck
oncology. In case of discrepancies between the response
classification of the reviewer and the treating clinician
the CT-scans or MRI's were reviewed by a team of the
author's but in doubt the response was always rounded
down to the least favorable response category. Ten pa-
tients were considered not evaluable for the following
reasons: initial measurements performed with other
techniques than at follow-up (five patients), missing
CT-scans one patient, early death three patients, lost to
follow-up one patient. In the amifostine group two
patients obtained a complete response and 17 a partial
response out of 30 evaluable patients (63%; 53% of
eligible patients); in the cisplatin only arm 34 patients
were evaluable for response and 17 had a partial re-
sponse (50%; 46% of eligible patients). In patients with
locally advanced disease there were 23 evaluable patients
in the amifostine arm (1 CR and 15 PR: response rate
70%) and 26 in the cisplatin only arm (partial response
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in 13 patients: 50%). The low number of complete res-
ponders can be attributed to the early time of response
evaluation and the very strict criteria with which CT-
scans and MRl's were judged. As all patients with
locally advanced disease had radiotherapy starting two
weeks after the last cisplatin administration and the
treatment was left free for the other patient categories
no information can be given on response duration. Anal-
ysis of survival will be a subject of a later report.
As a significant protection by amifostine of renal
function and hearing could not be demonstrated with
this cisplatin schedule the group decided not to embark
on the dose escalation study.
Discussion
The incidence of head and neck cancer in the western
world is still rising and most patients present at diagnosis
with stage III or IV tumors. In locally advanced disease
cisplatin containing neoadjuvant chemotherapy is fre-
quently given although the real value of neoadjuvant
chemotherapy still has to be proven [4]. The combina-
tion of cisplatin with continuous infusion of fluorouracil
is generally considered to be the standard regimen.
However, side effects of this regimen (nausea, vomiting,
lengthy hospital stays, phlebitis- or the need for central
venous access) are a frequent cause of patient noncom-
pliance. Regimens with shorter hospital stays might be
more attractive to this particular patient group.
We previously explored a regimen with weekly ad-
ministration of cisplatin, aiming at a treatment with a
high dose intensity. The patient compliance in that study
was good and 60% of the evaluable patients responded
[8]. Toxicity, mainly thrombocytopenia, ototoxicity and
renal toxicity, precluded completion of the six planned
cycles in 40% of the patients, however, and the median
cisplatin dose intensity achieved was 60 mg/m2/week in
stead of the planned 80 mg/m2/week. Measures to
reduce the toxicity of this schedule were thus considered
worthwhile to explore.
Amifostine (WR-2721) is one of several cytoprotec-
tive drugs that entered clinical trials the last decade.
WR-2721 is a prodrug; the active metabolite, the free
thiol WR-1065 accumulates rapidly in normal cells but
slowly in tumor cells [22]. WR-1065 is a potent scavenger
of oxygen-free radicals and binds to active platinum
species thereby preventing platinum-DNA adduct for-
mation [23]. Because of the short half life of WR-1065
the drug was administered directly before cisplatin and
for the same reason cisplatin was administered over one
hour. As the phase I studies of amifostine suggested that
patients with head and neck cancer are more prone to
hypotension than patients with other tumor types we
started a feasibility study first to test the combination of
amifostine and cisplatin in a weekly regimen. With an
amifostine dose of 740 mg/m2 the risk of hypotension
was low. In the randomized study hypotension grade 3 +
4 occurred in five patients and always during the first or
second cycle. Other side effects reported, palpitations,
feelings of anxiety and drowsiness, were mainly related
to the hypotensive episodes and were of minor impor-
tance. A typical side effect is sneezing.
In the present study the comparison of cisplatin
toxicities was the main interest. Protection of bone
marrow toxicity by amifostine was limited to protection
of thrombocytopenia only. Treatment delays due to hem-
atologic toxicity never occurred before the fourth cycle.
The number of cycles delayed because of hematologic
toxicity was not different between both arms and. the
cisplatin dose-intensity after three cycles and over-all are
equal between both arms. The observation of protection
against thrombocytopenia is in agreement with observa-
tions in animal studies with carboplatin and fluorouracil
where amifostine selectively protected the animals from
developing thrombocytopenia [22]. It is also in agree-
ment with other randomized studies in patients treated
with various cytotoxic agents (alkylating agents, platinum
compounds, mitomycin C) with or without amifostine
[12-14].
We could not show a protective effect on renal toxicity
in this study. The incidence of renal toxicity was low in
both arms of the study. Therefore, any additional effect
of amifostine would have been difficult to show. This low
incidence can be explained by the use of hypertonic
saline and the vigorous hydration program in this study.
In a large randomized study in ovarian cancer a signifi-
cant protective effect of amifostine on the renal function
was shown [12]. In that study, patients were treated with
cisplatin-cyclophosphamide with or without amifostine
every three weeks. Apart from the addition of cyclo-
phosphamide, a less vigorous hydration schedule and a
higher dose of cisplatin per cycle may have contributed
to the higher incidence of renal toxicity as in the group
treated without amifostine 30% of the patients had a
decrease of > 40% in the calculated creatinine clearance.
With respect to the development of hypomagnesemia,
an indication of tubular damage induced by cisplatin
[24], the occurrence of grade 2 and 3 hypomagnesemia
was significantly less in the combination arm, which
is in agreement with the results of the study of Kemp et
al. [12]. Although major symptoms such as epileptic
seizures, ventricular tachycardias and cortical blindness
fortunately occur only in a minority of patients, minor
complaints such as muscle weakness, anorexia and nau-
sea are frequently reported. Several randomized studies
showed the importance but also the limited succes of
magnesium supplementation [25] making the protective
effect of amifostine of value in the subgroup of patients
at risk for this side effect.
The third cisplatin toxicity on which amifostine showed
a protective effect in a previous study is neurotoxicity
[11]. In our study measurement of the VPT was selected
as VPTs are a more objective and sensitive indicator of
neurotoxicity than the clinical CTC criteria [26, 27]. As
cisplatin neurotoxicity can become manifest up to three
months after the last cisplatin dose [28] VPTs were
separately analyzed in the patients with three months
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follow-up. Unfortunately the number of patients with
long-term follow-up was less than expected which ham-
pers a complete analysis. The increase in VPTwas less in
the amifostine arm and VPT values stayed well below
the values we obtained in previous studies with cisplatin
only, which is highly suggestive of a protective effect of
amifostine [28]. Additional studies with more patients
and more complete follow-up data will be needed.
The fourth major cisplatin toxicity in which we were
interested, and which is reported frequently in high-dose
schedules, is ototoxicity. In contrast to neurotoxicity, the
risk of ototoxicity is more dependent on the cisplatin
dose per cycle than the cumulative dose. Also the cispla-
tin peak plasma levels, which are high with a one-hour
infusion, are of influence [29, 30].
In this study a protective effect was not shown,
neither when analyzed by audiometry nor when graded
on complaints. A recently published study on protection
of cisplatin induced ototoxicity in hamsters showed that
amifostine had no effect while sodium thiosulfate was
more active [30]. This preclinical study fits well with our
observation and further studies on prevention of ototox-
icity are of utmost importance.
Amifostine itself had manageable side effects. The
drug compares in this way favorable with other cyto-
protective agents. Diethyldithiocarbamate (DDTC), a
heavy metal chelating agent, is an effective protector in
animal studies. However, its side effects in patients limit
its use [32]. Sodiumthiosulfate and probenecid [33, 34]
have the disadvantage that they only protect the kidneys
while for sodiumthiosulphate inhibition of cisplatin ac-
tivity is suggested [34]. A recently published randomized
phase II trial in advanced gastric cancer, treated with a
weekly chemotherapy regimen of cisplatin 40 mg/m2 plus
or minus reduced gluthation (GSH), showed signifi-
cantly less neurotoxicity and less treatment delays due
to thrombocytopenia in the GSH arm [35]. In that study
no clinical ototoxicity was observed, probably related to
the low cisplatin dose per cycle. Data on nephrotoxicity
or mineral disorders were not reported.
The response rate we observed in locally advanced
disease of 70% in the combination arm and 50% in the
cisplatin only arm is somewhat lower than reported for
most combination regimens [2-4], however, the patients
in our study all had extensive irresectable disease. The
fear that amifostine would not only protect normal
tissues but also tumor tissue is not confirmed as the
response rate in the amifostine arm was even slightly
higher than in the cisplatin only arm. Amifostine thus
showed a protective effect in this study on three organ
systems. However, in the combination arm the cisplatin-
dose intensity was not higher than in the cisplatin only
arm. For this reason, and due to the lack of protection
on ototoxicity, it was decided not to continue with the
planned dose-escalation study. As amifostine also pro-
tects normal tissues from late radiation damage [11]
further studies with amifostine and cisplatin or carbo-
platin plus radiotherapy in head and neck cancer are
warranted.
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